Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib

Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor that has been independently researched and developed and has independent intellectual property rights in the People’s Republic of China. Clinical trials have demonstrated that the response to icotinib among advanced non-small-cell lung cancer (NSCLC) patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. Since being launched August 2011 in the People’s Republic of China, icotinib has been widely used in clinics, and has become an important treatment option for Chinese patients with advanced NSCLC. The present study presents the Phase I, II, and III clinical trials of icotinib and discusses current clinical applications in the People’s Republic of China and future research directions.

• Publication year

  2014

• Venue

  OncoTargets and Therapy

• Publication date

  2014-05-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/OTT.S49233PMID 24876785PMCID 4037325
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.

  2014cited by this paper
• Clinical observation of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer

  2014influential reference
• Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

  2014cited by this paper
• Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects

  2014cited by this paper
• Efficacy and safety of icotinib in Chinese patients with advanced nonsmall cell lung cancer after failure of chemotherapy

  2014cited by this paper
• Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling.

  2013cited by this paper
• Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.

  2013influential reference
• 盐酸埃克替尼治疗晚期复发非小细胞肺癌的临床疗效

  2013cited by this paper
• A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma

  2013cited by this paper
• 盐酸埃克替尼一线治疗晚期肺腺癌的临床疗效观察

  2013cited by this paper
• Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.

  2013cited by this paper
• 1989年-2008年中国肺癌发病性别、城乡差异及平均年龄趋势分析

  2013cited by this paper
• 埃克替尼在晚期非小细胞肺癌EGFR状态明确的患者中的疗效分析

  2013cited by this paper
• Efficacy of Icotinib for Advanced Lung Adenocarcinoma

  2013influential reference
• Clinical value in treatment with icotinib as first- line therapy in advanced non- small cell lung cancer

  2013influential reference
• Efficacy and toxicity of icotinib hydrochloride in 66 patients with advanced non-small cell lung cancer

  2013cited by this paper
• Treatment with high-dose icotinib in a lung adenocarcinoma patient with epidermal growth factor receptor mutation

  2013cited by this paper
• Efficacy and safety of icotinib hydrochloride in the treatment of 50 patients with advanced adenocarcinoma of lung

  2013cited by this paper
• Efficacy of icotinib hydrochloride in the treatment of 31 patients with advanced squamous cell lung carcinoma

  2013influential reference
• Clinical Observation of Icotinib Hydrochloride in the Treatment for Advanced Non-small Cell Lung Cancer

  2013cited by this paper
• A retrospective study of icotinib for patients with brain metastases from non-small cell lung cancer

  2013influential reference
• Successful treatment of one patient with advanced non-small cell lung cancer with icotinib hydrochloride in replacement of gefitinib

  2013influential reference
• Short-term Response and Toxicity of Icotinib Hydrochloride in the Treatment for Advanced Non-small Cell Lung Cancer

  2012cited by this paper
• Safety,toleration and therapeutic effect of the new drug icotinib hydrochloride in treating Chinese patients with non-small cell lung cancers

  2012cited by this paper
• Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

  2012cited by this paper
• [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].

  2012cited by this paper
• Clinical efficacy of icotinib in treatment of seventeen non-smokers with advanced lung adenocarcinoma

  2012cited by this paper
• Retrospective study of erlotinib in patients with advanced squamous lung cancer.

  2012cited by this paper
• Erlotinib in patients with advanced lung squamous cell carcinoma

  2012cited by this paper
• Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.

  2011cited by this paper
• Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.

  2011cited by this paper
• Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.

  2011cited by this paper
• Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

  2011influential reference
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Pharmacology and clinical evaluation of icotinib hydrochloride

  2009influential reference
• submit your manuscript | www.dovepress.com

  year unknowncited by this paper

• Intersection between lung cancer and neuroscience: opportunities and challenges.

  2025cites this paper
• Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis

  2024cites this paper
• Gallic acid enhances the antitumor activity of Icotinib hydrochloride in non-small cell lung cancer via of Hippo-YAP signaling pathway in vitro and in vivo

  2022cites this paper
• Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance

  2022cites this paper
• Application of physiologically based pharmacokinetic modelling for the prediction of drug–drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes

  2022cites this paper
• Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion

  2021cites this paper
• Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China

  2021cites this paper
• First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence

  2021cites this paper
• Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion.

  2019influential citation
• Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line.

  2019cites this paper
• Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation

  2018cites this paper
• Icotinib enhances lung cancer cell radiosensitivity in vitro and in vivo by inhibiting MAPK/ERK and AKT activation

  2018cites this paper
• The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis

  2018cites this paper
• A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo

  2017cites this paper
• Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies

  2016cites this paper
• Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study

  2016cites this paper
• Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients

  2015influential citation
• Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer.

  2015cites this paper
• Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells

  2014cites this paper